不同四种方案治疗骨髓增生异常综合征临床研究  

The study of erythopietin receptor and researched 4 different plans for curing MDS

作　　者：邓成莲[1] 文国泰[1] 马艳[1] 林燕[1] 

机构地区：[1]四川省医学科学院附属医院血液科,四川简阳641400

出　　处：《四川医学》2008年第9期1126-1128,共3页Sichuan Medical Journal

摘　　要：目的研究不同四种方案治疗骨髓增生异常综合征(MDS)疗效,寻求有效的治疗的策略。方法经FAB标准确诊的MDS患者39例在积极支持治疗下,按个体差异采取不同的化疗方案进行诱导化疗。结果小剂量阿糖胞苷(LD-Ara-C)组治疗10例,完全缓解(CR)率13.5%;MA组治疗8例,CR率45.0%;DA组治疗6例,CR率40.5%;CAG组治疗15例,CR率60.5%,PR者经2个疗程治疗后,余改用其它方案治疗。结论CAG方案治疗MDS,CR率高。不良反应小,为MDS患者延长生存期,改善生活质量,提供一种可行的方案。Objective To study the researched 4 different plans for curing MDS, and looking for the strategy which one effectivly and curly .Methods By way of FAB to diagnose standardly,39 MDS patients were cured actively.They were adopted the different plans for individual difference to carry on abduction. Results Min-dose LD-Ara-C group cured 10 examples, all relieve CR pereentage 13.5% ; MA group cured 8 examples, CR percentage 45.0% ;DA group cured 6 examples, CR percentage 40.5 % ;CAG group cured 15 exampies, CR percentage 60.5 % ; PR after two course of treatment, eured by another plans. Conclusion CAG plans cured MDS, CR percentage high. Toxin side effect small, prolonged growth times for MDS patients, change the living quality, offered one plan which one was practically.

关 键 词：骨髓增生异常综合征 小剂量阿糖胞苷 米托蒽醌 柔红酶素 

分 类 号：R551.3[医药卫生—血液循环系统疾病]